AMT-116 vs standard chemo for advanced non-squamous lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called AMT-116 against a standard chemotherapy (docetaxel) for people with advanced non-squamous lung cancer that has gotten worse after previous treatments. The goal is to see which works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced or metastatic non-squamous non-small cell lung cancer (a common type of lung cancer that is not the squamous kind).
- Your cancer has no EGFR gene mutation, or has other gene changes that are not EGFR mutations.
- You have already had platinum-based chemotherapy and an immunotherapy (anti-PD-1/PD-L1), and your cancer got worse after that.
- You have had no more than one line of chemotherapy for advanced disease.
- You are well enough to carry out normal daily activities (ECOG 0 or 1) and have good organ function (heart, liver, kidneys, blood counts).
- You are between 18 and 80 years old and have a life expectancy of at least 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new mix of high and low dose radiation along with chemotherapy and immunotherapy for people with locally advanced non-small cell lung cancer. It aims to see if this combination can improve treatment outcomes.
This trial tests a combination of two drugs—SCTB41 (a new immunotherapy) and docetaxel (a chemotherapy)—in patients with advanced non-small cell lung cancer who have already tried other treatments. The goal is to see if this combination can slow or stop cancer growth.
This trial tests a new drug called AMT-116 in people with advanced solid tumors that have not responded to prior treatment. The goal is to see if it is safe and effective.
This trial tests a combination of two experimental drugs (AMT-116 and ivosidan) for patients with advanced lung cancer that cannot be removed by surgery. The study aims to see if this combination can help shrink tumors and improve survival.
This trial tests how well chemotherapy works for people with stage IV non-small cell lung cancer that has spread. It is for those who have already tried at least one prior treatment and are healthy enough for more therapy.
This Phase 1 trial tests AMT-116, an investigational medicine, in people with advanced solid cancers that can’t be removed by surgery and have gotten worse after standard treatment. It looks for the best safe dose and early signs the treatment may shrink tumors or slow growth.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.